APA (7th ed.) Citation

Yu, R., Diep, J., Karwatowska-Prokopczuk, E., & Gao, X. (2025). Clinical Pharmacology of Olezarsen, a Novel ApoC-III Targeted Antisense Inhibitor, for Reducing Triglycerides in Patients with Familial Chylomicronemia Syndrome. Journal of clinical lipidology, 19(3), e108-e109. https://doi.org/10.1016/j.jacl.2025.04.156

Chicago Style (17th ed.) Citation

Yu, Rosie, John Diep, Ewa Karwatowska-Prokopczuk, and Xiang Gao. "Clinical Pharmacology of Olezarsen, a Novel ApoC-III Targeted Antisense Inhibitor, for Reducing Triglycerides in Patients with Familial Chylomicronemia Syndrome." Journal of Clinical Lipidology 19, no. 3 (2025): e108-e109. https://doi.org/10.1016/j.jacl.2025.04.156.

MLA (9th ed.) Citation

Yu, Rosie, et al. "Clinical Pharmacology of Olezarsen, a Novel ApoC-III Targeted Antisense Inhibitor, for Reducing Triglycerides in Patients with Familial Chylomicronemia Syndrome." Journal of Clinical Lipidology, vol. 19, no. 3, 2025, pp. e108-e109, https://doi.org/10.1016/j.jacl.2025.04.156.